Skip to main content
Top
Published in:

09-07-2022 | Obesity | EDITORIAL

Obesity and cancer

Authors: Emily J. Gallagher, Derek LeRoith

Published in: Cancer and Metastasis Reviews | Issue 3/2022

Login to get access

Excerpt

Globally, the prevalence of obesity has almost tripled since 1975, according to the World Health Organization (WHO). It affects adults and children and not only those living in high-income countries; the rates of obesity have increased dramatically in middle- and low-income countries. In children and adolescents, obesity increased from 0.7 to 5.6% in boys, and from 0.9 to 7.8% in girls worldwide between 1975 and 2016 [1]. Obesity is a risk factor for several health conditions, including cardiovascular diseases, diabetes, fatty liver disease, and a number of cancers. In 2016, the International Agency for Research on Cancer (IARC) identified 13 cancer sites that were associated with increased body mass index (BMI): esophagus (adenocarcinoma); gastric cardia; colon and rectum; liver; gallbladder; pancreas; breast (postmenopausal); corpus uteri; ovary; kidney (renal cell); meningioma; thyroid, and multiple myeloma [2]. In 2012, it was estimated that 3.9% of new cancers worldwide were attributable to overweight and obesity, and it has long been known that obesity is associated with cancer mortality [3]. …
Literature
1.
go back to reference Bluher, M. (2019). Obesity: Global epidemiology and pathogenesis. Nature Reviews Endocrinology, 15(5), 288–298.CrossRef Bluher, M. (2019). Obesity: Global epidemiology and pathogenesis. Nature Reviews Endocrinology, 15(5), 288–298.CrossRef
2.
go back to reference Lauby-Secretan, B., Scoccianti, C., Loomis, D., et al. (2016). Body fatness and cancer—Viewpoint of the IARC Working Group. New England Journal of Medicine, 375(8), 794–798.CrossRef Lauby-Secretan, B., Scoccianti, C., Loomis, D., et al. (2016). Body fatness and cancer—Viewpoint of the IARC Working Group. New England Journal of Medicine, 375(8), 794–798.CrossRef
3.
go back to reference Pearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M. J., & Ezzati, M. (2018). Worldwide burden of cancer attributable to diabetes and high body-mass index: A comparative risk assessment. The Lancet Diabetes and Endocrinology, 6(6), e6–e15.CrossRef Pearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M. J., & Ezzati, M. (2018). Worldwide burden of cancer attributable to diabetes and high body-mass index: A comparative risk assessment. The Lancet Diabetes and Endocrinology, 6(6), e6–e15.CrossRef
4.
go back to reference Larsson, S. C., & Burgess, S. (2021). Causal role of high body mass index in multiple chronic diseases: A systematic review and meta-analysis of Mendelian randomization studies. BMC Medicine, 19(1), 320.CrossRef Larsson, S. C., & Burgess, S. (2021). Causal role of high body mass index in multiple chronic diseases: A systematic review and meta-analysis of Mendelian randomization studies. BMC Medicine, 19(1), 320.CrossRef
5.
go back to reference Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7–33. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7–33.
6.
go back to reference Albain, K. S., Gray, R. J., Makower, D. F., et al. (2021). Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. Journal of the National Cancer Institute, 113(4), 390–399.CrossRef Albain, K. S., Gray, R. J., Makower, D. F., et al. (2021). Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. Journal of the National Cancer Institute, 113(4), 390–399.CrossRef
7.
go back to reference Diamantopoulou, Z., Castro-Giner, F., Schwab, F. D., et al. (2022). The metastatic spread of breast cancer accelerates during sleep. Nature, 607, 156–162. Diamantopoulou, Z., Castro-Giner, F., Schwab, F. D., et al. (2022). The metastatic spread of breast cancer accelerates during sleep. Nature, 607, 156–162.
8.
go back to reference Goodwin, P. J., Chen, B. E., Gelmon, K. A., et al. (2022). Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA, 327(20), 1963–1973.CrossRef Goodwin, P. J., Chen, B. E., Gelmon, K. A., et al. (2022). Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA, 327(20), 1963–1973.CrossRef
9.
go back to reference Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515.CrossRef Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515.CrossRef
10.
go back to reference Aminian, A., Wilson, R., Al-Kurd, A., et al. (2022). Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA, 327(24), 2423–2433. Aminian, A., Wilson, R., Al-Kurd, A., et al. (2022). Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA, 327(24), 2423–2433.
Metadata
Title
Obesity and cancer
Authors
Emily J. Gallagher
Derek LeRoith
Publication date
09-07-2022
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-022-10049-z

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now